Microformulations and Nanoformulations of Doxorubicin for Improvement of Its Therapeutic Efficiency.

IF 3 4区医学 Q2 PHARMACOLOGY & PHARMACY Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2020-01-01 DOI:10.1615/CritRevTherDrugCarrierSyst.2020034470

Mehran Alavi, Ali Nokhodchi

{"title":"Microformulations and Nanoformulations of Doxorubicin for Improvement of Its Therapeutic Efficiency.","authors":"Mehran Alavi, Ali Nokhodchi","doi":"10.1615/CritRevTherDrugCarrierSyst.2020034470","DOIUrl":null,"url":null,"abstract":"<p><p>Non-selectivity and dose-dependent side effects of doxorubicin (DOX), particularly cardio-toxicology as well as multidrug resistance in various tumor cells, have increased the demand for novel formulations with suitable efficiency and safety. Microformulations and nanoformulations have been shown to have satisfactory responses compared with that of conventional formulations. In this review, recent advances alongside the advantages and disadvantages of microformulations and nanoformulations are discussed. Doxil and Caelyx (PEGylated forms) as well as Myocet (non-PEGylated form) are presented as approved liposomal forms by the U.S. Food and Drug Administration to increase blood circulation half-life of DOX. Liposomes, micelles, hydrogels, lipid nanoparticles (NPs), polymeric NPs, polymersomes, metal/metal oxide NPs, mesoporous silica NPs, carbon-based NPs, and quantum dots are all major carriers for DOX and discussed accordingly. Considering all extracellular and intracellular conditions of cancer cells is an indispensable affair to obtain promising DOX carriers. Lack of a comprehensive related to drug-resistance cancer cells particularly in metastasis stages is an important hindrance to get acceptable results. Understanding of the drug resistance mechanisms in cancers cells particularly, in metastasis stages, is a critical factor to prepare efficient formulations.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Reviews in Therapeutic Drug Carrier Systems","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2020034470","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 9

Abstract

Non-selectivity and dose-dependent side effects of doxorubicin (DOX), particularly cardio-toxicology as well as multidrug resistance in various tumor cells, have increased the demand for novel formulations with suitable efficiency and safety. Microformulations and nanoformulations have been shown to have satisfactory responses compared with that of conventional formulations. In this review, recent advances alongside the advantages and disadvantages of microformulations and nanoformulations are discussed. Doxil and Caelyx (PEGylated forms) as well as Myocet (non-PEGylated form) are presented as approved liposomal forms by the U.S. Food and Drug Administration to increase blood circulation half-life of DOX. Liposomes, micelles, hydrogels, lipid nanoparticles (NPs), polymeric NPs, polymersomes, metal/metal oxide NPs, mesoporous silica NPs, carbon-based NPs, and quantum dots are all major carriers for DOX and discussed accordingly. Considering all extracellular and intracellular conditions of cancer cells is an indispensable affair to obtain promising DOX carriers. Lack of a comprehensive related to drug-resistance cancer cells particularly in metastasis stages is an important hindrance to get acceptable results. Understanding of the drug resistance mechanisms in cancers cells particularly, in metastasis stages, is a critical factor to prepare efficient formulations.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

阿霉素微制剂和纳米制剂对其治疗效果的改善。

阿霉素(DOX)的非选择性和剂量依赖性副作用，特别是心脏毒理学和多种肿瘤细胞的多药耐药，增加了对具有适当效率和安全性的新型制剂的需求。与常规制剂相比，微制剂和纳米制剂具有令人满意的反应。在这篇综述中，最近的进展以及微制剂和纳米制剂的优缺点进行了讨论。Doxil和Caelyx(聚乙二醇化形式)以及心肌(非聚乙二醇化形式)被美国食品和药物管理局批准为脂质体形式，以增加DOX的血液循环半衰期。脂质体、胶束、水凝胶、脂质纳米颗粒(NPs)、聚合物NPs、聚合体、金属/金属氧化物NPs、介孔二氧化硅NPs、碳基NPs和量子点都是DOX的主要载体，并进行了相应的讨论。考虑癌细胞的细胞外和细胞内条件是获得有前途的DOX载体必不可少的事情。缺乏全面的与耐药相关的肿瘤细胞，特别是在转移阶段，是获得可接受结果的重要障碍。了解癌细胞的耐药机制，特别是在转移阶段，是制备有效制剂的关键因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Critical Reviews in Therapeutic Drug Carrier Systems 医学-药学

CiteScore

5.50

自引率

18.50%

发文量

审稿时长

>12 weeks

期刊介绍： Therapeutic uses of a variety of drug carrier systems have significant impact on the treatment and potential cure of many chronic diseases, including cancer, diabetes mellitus, psoriasis, parkinsons, Alzheimer, rheumatoid arthritis, HIV infection, infectious diseases, asthma, and drug addiction. Scientific efforts in these areas are multidisciplinary, involving the physical, biological, medical, pharmaceutical, biological materials, and engineering fields. Articles concerning this field appear in a wide variety of journals. With the vast increase in the number of articles and the tendency to fragment science, it becomes increasingly difficult to keep abreast of the literature and to sort out and evaluate the importance and reliability of the data, especially when proprietary considerations are involved. Abstracts and noncritical articles often do not provide a sufficiently reliable basis for proper assessment of a given field without the additional perusal of the original literature. This journal bridges this gap by publishing authoritative, objective, comprehensive multidisciplinary critical review papers with emphasis on formulation and delivery systems. Both invited and contributed articles are subject to peer review.